高级检索
当前位置: 首页 > 详情页

RETRACTED: Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells (Retracted article. See vol. 338, pg. 331, 2013)

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu, Oita 8795593, Japan [2]Hebei Med Univ, Hosp 4, Dept Obstet & Gynecol, Shijiazhuang, Peoples R China [3]Oita Univ, Fac Med, Dept Mol Pathol, Yufu, Oita 8795593, Japan [4]Oita Univ, Fac Med, Dept Neurosurg, Yufu, Oita 8795593, Japan [5]Oita Univ, Fac Med, Dept Obstet & Gynecol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan
出处:
ISSN:

关键词: Triptolide Cell cycle Apoptosis Microarray Gynecologic cancer

摘要:
Triptolide (TPL), a bioactive component of the Chinese medicinal herb Tripterygium wilfordii Hook F, induces apoptosis in some lines of human tumor cells. However, the effect of TPL on gynecologic cancer cells has not yet been well-described. We investigated the effects of TPL on cell growth, cell cycle, and apoptosis in endometrial and ovarian cancer cell lines. Furthermore, we examined global changes in gene expression after treatment with TPL. By using a list of 20 differentially expressed genes, Western blot analyses were performed on five endometrial and ovarian cancer cell lines. All cell lines were sensitive to the growth-inhibitory effect of TPL. TPL increased the proportion of cells in the S-phase of the cell cycle and induced apoptosis. cDNA microarray assay demonstrated that the treatment with TPL changed the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers. Of the gene expression changes induced by TPL treatment, up-regulation of LRAP, CDH4, and SFRP1 and down-regulation of cystatin, TNNT 1, and L1-CAM were confirmed using Western blot analysis in all the cell lines examined. We found a strong anticancer activity of TPL and identified some potential target genes of this drug, raising hopes that TPL may become a useful therapy for endometrial and ovarian cancers. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

基金:

基金编号: FK344 21592139

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2010]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2010]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者机构: [1]Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu, Oita 8795593, Japan [2]Hebei Med Univ, Hosp 4, Dept Obstet & Gynecol, Shijiazhuang, Peoples R China
通讯作者:
通讯机构: [5]Oita Univ, Fac Med, Dept Obstet & Gynecol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39766 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号